The Pharmacokinetics and Pharmacodynamics of Iron Preparations
Open Access
- 4 January 2011
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 3 (1), 12-33
- https://doi.org/10.3390/pharmaceutics3010012
Abstract
Standard approaches are not appropriate when assessing pharmacokinetics of iron supplements due to the ubiquity of endogenous iron, its compartmentalized sites of action, and the complexity of the iron metabolism. The primary site of action of iron is the erythrocyte, and, in contrast to conventional drugs, no drug-receptor interaction takes place. Notably, the process of erythropoiesis, i.e., formation of new erythrocytes, takes 3−4 weeks. Accordingly, serum iron concentration and area under the curve (AUC) are clinically irrelevant for assessing iron utilization. Iron can be administered intravenously in the form of polynuclear iron(III)-hydroxide complexes with carbohydrate ligands or orally as iron(II) (ferrous) salts or iron(III) (ferric) complexes. Several approaches have been employed to study the pharmacodynamics of iron after oral administration. Quantification of iron uptake from radiolabeled preparations by the whole body or the erythrocytes is optimal, but alternatively total iron transfer can be calculated based on known elimination rates and the intrinsic reactivity of individual preparations. Degradation kinetics, and thus the safety, of parenteral iron preparations are directly related to the molecular weight and the stability of the complex. High oral iron doses or rapid release of iron from intravenous iron preparations can saturate the iron transport system, resulting in oxidative stress with adverse clinical and subclinical consequences. Appropriate pharmacokinetics and pharmacodynamics analyses will greatly assist our understanding of the likely contribution of novel preparations to the management of anemia.This publication has 63 references indexed in Scilit:
- Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorderArzneimittelforschung, 2010
- Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemiaArzneimittelforschung, 2010
- Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytolClinical Kidney Journal, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyThe New England Journal of Medicine, 2009
- Ferric CarboxymaltoseDrugs, 2009
- Non-transferrin-bound iron in plasma following administration of oral iron drugsBioMetals, 2007
- Identification of an Intestinal Folate Transporter and the Molecular Basis for Hereditary Folate MalabsorptionCell, 2006
- Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound ironEuropean Journal of Clinical Investigation, 2004
- Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytesImmunology & Cell Biology, 1990
- Correlation of postabsorptive serum iron increase and erythrocyte-59Fe-incorporation with the whole body retention of absorbed59FeJournal of Molecular Medicine, 1982